# OnCo record drug-price-transparency (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/drug-price-transparency/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "drug-price-transparency" ;
  schema:name "Oncology drug pricing and price transparency"@en ;
  schema:description "New cancer drugs commonly launch above $150,000-$250,000 per year in the US, with prices set without reference to benefit and hidden behind rebates; other countries negotiate or assess cost-effectiveness. Pricing policy determines who gets treated."@en ;
  schema:url <https://onco.cc/terms/drug-price-transparency/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Prescription_drug_prices_in_the_United_States> ;
  schema:citation <https://doi.org/10.1016/S1470-2045(20)30139-X>, <https://icer.org/>, <https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation> ;
  onco:tag "gap-fill", "policy" ;
  onco:related <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/global-oncology-access/>, <https://onco.cc/terms/biosimilar/>, <https://onco.cc/terms/accelerated-approval/> ;
  onco:terms <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/who-essential-medicines/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-vokinger-lancet-oncol/> .